Loading...
•
Jun 30, 2023
Regeneron Q2 2023 Earnings Report
Regeneron's financial performance was strong in Q2 2023, driven by diversified revenue streams and pipeline advancements.
Key Takeaways
Regeneron reported an 11% increase in revenue to $3.16 billion for the second quarter of 2023. GAAP diluted EPS was $8.50, and non-GAAP diluted EPS was $10.24. The company progressed its pipeline, including aflibercept 8 mg, and saw a 33% increase in Dupixent global net sales.
Total revenues increased by 11% to $3.16 billion compared to Q2 2022.
Dupixent global net sales (recorded by Sanofi) increased by 33% to $2.79 billion compared to Q2 2022.
EYLEA U.S. net sales were $1.50 billion.
GAAP diluted EPS was $8.50, and non-GAAP diluted EPS was $10.24.
Revenue by Segment
Forward Guidance
Regeneron updated its full year 2023 financial guidance.
Positive Outlook
- GAAP R&D guidance updated to $4.315–$4.455 billion.
- Non-GAAP R&D guidance updated to $3.825–$3.925 billion.
- GAAP SG&A guidance updated to $2.540–$2.680 billion.
- Non-GAAP SG&A guidance updated to $2.180–$2.280 billion.
- GAAP effective tax rate updated to 8%-9%.
Challenges Ahead
- No specific negative aspects were provided, the guidance update mainly involved adjustments to projected figures without highlighting explicit concerns or risks.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...